Drucken - Print

Selected publications

K. Althoff, A. Schramm

MYCN-mediated murine cancer models

Aging (Albany, NY) 9(4): 1084-1085 (2017)


R.A. Okimoto, F. Breitenbuecher, V.R. Olivas, W. Wu, B. Gini, M. Hofree, S. Asthana, G. Hrustanovic, J. Flanagan, A. Tulpule, C.M. Blakely, H.J. Haringsma, A.D. Simmons, K. Gowen, J. Suh, V.A. Miller, S. Ali, M. Schuler and T.G. Bivona

Inactivation of Capicua drives cancer metastasis.

Nat. Genet. doi:10.1038/ng.3728 (2016)


C. Göbel, F. Breitenbuecher, H. Kalkavan, P.S. Hähnel, S. Kasper, S. Hoffarth, K. Merches, H. Schild, K.S. Lang and M. Schuler

Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.

Cell Death and Disease 5, e1568; doi:10.1038/cddis.2014.53 (2014)


F. Breitenbuecher, S. Hoffarth, K. Worm, D. Cortes-Incio, T.C. Gauler, J. Köhler, T. Herold, K.-W. Schmid, L. Freitag, S. Kasper, and M. Schuler

Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small cell lung cancer patients. 

Plos One 9(1):e85350. doi:10.1371/journal.pone.0085350 (2014)


G. Hoffmann, F. Breitenbuecher, M. Schuler, and A. E. Ehrenhofer-Murray

A novel SIRT2 inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. 

J Biol Chem  (2013)


M. Wiesweg, S. Ting, H. Reis, K. Worm, S. Kasper, M. Tewes, A. Welt, H. Richly, J. Meiler, S. Bauer, J. Hense, T.C. Gauler, J. Köhler, W.E. Eberhardt, K. Darwiche, L. Freitag, G. Stamatis, F. Breitenbücher, J. Wohlschläger, D. Theegarten, C. Derks, D. Cortes-Incio, G. Linden, S. Skottky, P. Lüttkes, A. Dechêne, A. Paul, P. Markus, K.W. Schmid, and M. Schuler

Feasibility of preemptive biomarker profiling for personalized early clinical drug development at a comprehensive cancer center.

Eur. J. Cancer 49: 3076-3082 (2013)


M. Molzan, S. Kasper, L. Röglin, M. Skwarzynska, T. Sassa, T. Inoue, F. Breitenbuecher, J. Ohkanda, N. Kato*, M. Schuler*, and C. Ottmann*

Stabilization of physical RAF/14-3-3 interaction by Cotylenin A as treatment strategy for RAS mutant cancers (*shared corresponding authorship).

ACS Chem Biol 20: 1869-1875 (2013)


S. Kasper, F. Breitenbuecher, H. Reis, S. Brandau, K. Worm, J. Koehler, A. Paul, T. Trarbach, K.W. Schmid, and M. Schuler

Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.

Oncogene 32: 2873-2881 (2013)


J. Meiler, M. Guyot, S. Hoffarth, E. Wesarg, Y. Höhn, F. Breitenbuecher, M. Schuler

Individual dose and scheduling determine the efficacy of combining anticancer agents with a kinase inhibitor in non-small cell lung cancer

J Cancer Res Clin Oncol. 138: 1385-1394 (2012)


B. Markova, P.S. Hähnel, S. Kasper, S. Herbertz, M. Schuler and F. Breitenbuecher

Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.

J Cancer Res Clin Oncol. 138:545-54 (2012)


S. Becker, B. Markova, R. Wiewrodt, S. Hoffarth, P.S. Hähnel, S. Pleiner, L. Schmidt, F. Breitenbuecher and M. Schuler

Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer.

J Thorac Oncol. 6:1976-1983 (2011)


I.B. Petry, E. Fieber, M. Schmidt, M. Gehrmann, S. Gebhard, M. Hermes, W. Schormann, S. Selinski, E. Freis, H. Schwender, M. Brulport, K. Ickstadt, J. Rahnenführer, L. Maccoux, J. West, H. Kölbl, M. Schuler, and J.G. Hengstler

ERBB2 induces an anti-apoptotic expression pattern of Bcl-2 family members in node negative breast cancer.

Clin. Cancer Res. 16:451-460 (2010)


B. Markova, C. Albers, F. Breitenbuecher, J.V. Melo, J. Duyster, T. Brümmendorf, F. Heidel, D.B. Lipka, C. Huber, and T. Fischer

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1 driven activation of mTOR/p70S6-kinase pathway.

Oncogene 29:739-751 (2010)


S. Thaler, P.S. Hähnel, A. Schad, R. Dammann, and M. Schuler

RASSF1A mediates p21Cip1/Waf1- dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt.

Cancer Res. 69:1748-1757 (2009)


C. Stolz, G. Hess, P.S. Hähnel, F. Grabellus, S. Hoffarth, K.W. Schmid, and M. Schuler

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to Rituximab-induced apoptosis.

Blood 112:3312-3321 (2008)


P.S. Hähnel, S. Thaler, E. Antunes, Ch. Huber, M. Theobald, and M. Schuler

Targeting AKT signaling sensitizes cancer to cellular immunotherapy.

Cancer Res. 68:3899-3906 (2008)


C.A. Marques, P.S. Hähnel, C. Wölfel, S. Thaler, Ch. Huber, M. Theobald, and M. Schuler

An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte- mediated tumor suppression.

Blood 111:1413-1419 (2008)


S. Hoffarth, A. Zitzer, R. Wiewrodt, P.S. Hähnel, V. Beyer, A. Kreft, S. Biesterfeld, and M. Schuler

pp32/PHAPI determines the apoptosis response of non-small-cell lung cancer. 

Cell Death Differ. 15:161-170 (2008)